Pauline Funchain, MD, Cleveland Clinic, Cleveland, OH, shares findings from the intergroup S1404 Phase III trial (NCT02506153) comparing pembrolizumab to high-dose interferon or ipilimumab in patients with high-risk resected melanoma. The analysis aimed to assess if adjuvant pembrolizumab would offer overall survival or relapse-free survival (RFS) benefits in comparison to the two FDA-approved adjuvant treatment options. The results from over 1300 patients demonstrated that pembrolizumab elicited a statistically significant improvement in RFS compared to either high-dose interferon or ipilimumab. No statistically significant improvement in overall survival was shown in the pembrolizumab arm. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Pauline Funchain, MD has received research funds from Pfizer and BMS.